An automated anti-nephrin assay detects more positives and tracks relapse in childhood nephrotic syndrome

Design

Diagnostic assay development and cohort validation

Population

121 children with biopsy-confirmed minimal change disease or primary FSGS, plus controls

Primary outcome

Agreement with immunoprecipitation-Western blot; clinical associations

Effect

Concordance 86.8% (kappa 0.714); positivity 41.3% vs 28.1% by reference method

Anti-nephrin antibodies are increasingly recognised in minimal change disease and FSGS, but testing has relied on research methods that vary between laboratories. A Chinese group built an automated chemiluminescence immunoassay and tested it in 121 children with biopsy-proven minimal change disease or primary FSGS, alongside disease controls and healthy people, comparing it with immunoprecipitation-Western blot.

The two methods agreed in 86.8% of samples (kappa 0.714). The automated assay detected antibodies more often in minimal change disease or FSGS (41.3% vs 28.1%), including low-level positives. Positivity at presentation was associated with heavier proteinuria, lower albumin and steroid-sensitive disease; higher levels predicted shorter relapse-free survival; and positivity during remission was associated with relapse within three months.

If confirmed, a standard automated test could help separate antibody-mediated podocytopathy from genetic forms, and flag children at risk of relapse. For now this is a single-group validation, and the assay is not routinely available.

• Anti-nephrin antibodies are a marker of autoimmune podocytopathy in some children with nephrotic syndrome.
• Antibody positivity during remission was associated with relapse within three months in this cohort.
• Consider anti-nephrin testing where available when distinguishing immune from genetic disease.
• Do not change immunosuppression on an antibody result alone outside a research setting.

Why it matters

A practical, automated test could move anti-nephrin antibodies from research into everyday classification of podocytopathies.

Don't overread it

A single-centre validation; the relapse associations need confirmation before they guide therapy.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.